表紙:体外診断薬(IVD)市場の動向と最新情報:2024年3月
市場調査レポート
商品コード
1456202

体外診断薬(IVD)市場の動向と最新情報:2024年3月

In Vitro Diagnostic (IVD) Trends and Market Update: March 2024

出版日: | 発行: Kalorama Information | ページ情報: 英文 55 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.16円
体外診断薬(IVD)市場の動向と最新情報:2024年3月
出版日: 2024年03月26日
発行: Kalorama Information
ページ情報: 英文 55 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

診断検査はヘルスケアの基本となっており、医師による病状の診断や治療法の決定に役立っています。COVID-19検査が総収益に影響を及ぼしたもの、中核的な診断分野は総じて成長を遂げています。新製品、世界の医療支出の変化、規制の変化、疾病動向などの要因により、市場は絶えず変化していますが、依然として回復力を維持しています。

業界が注目している主な成長分野には、次世代シーケンシング(NGS)、個別化医療、質量分析などがあります。免疫化学、ポイントオブケア(POC)検査、分子診断も大きな関心を集めており、IVDの将来において重要な役割を果たすと期待されています。体外診断用医薬品(IVD)市場は、絶え間ない技術革新を特徴とするダイナミックな市場です。

当レポートでは、体外診断薬(IVD)市場について調査し、市場の動向について最新の情報を提供しています。また、市場に参入する主要企業の動向についてもまとめています。

目次

第1章 世界のIVD市場-2024年3月更新

第2章 製品の動向と新開発

  • 新製品-2023年第4四半期および2024年第1四半期- コアIVD製品の発売、開発、動向
  • 免疫測定
  • 分子
  • 個別化医療と遺伝子検査
  • 有価証券
  • シーケンシング
  • 微生物学
  • COVID-19の主要動向-2023年第4四半期-2024年第1四半期

第3章 IVD市場の主要参入企業の結果

  • 競争リーダーの最新情報
  • 2023年第4四半期、2024年第1四半期のM&A活動
  • Abbott Laboratories
  • Becton Dickinson and Co
  • bioMerieux SA
  • Danaher Corporation
  • Exact Sciences, Inc.
  • Hologic, Inc.
  • QuidelOrtho Corporation
  • Roche Diagnostic
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific

第4章 新たな機会

  • 人工知能の将来動向
  • 自宅での検査
  • マルチプレックス検査
  • 遠隔医療
目次
Product Code: 24-046

Diagnostic testing has become a fundamental aspect of healthcare, aiding physicians in diagnosing conditions and determining treatments. Despite a decline in COVID-19 testing affecting total revenues, core diagnostic segments have generally experienced growth. Factors such as new products, changes in global health spending, regulatory shifts, and disease trends contribute to a constantly changing market, yet one that remains resilient.

Key growing segments attracting industry attention include next-generation sequencing (NGS), personalized medicine, and mass spectrometry. Immunochemistry, point-of-care (POC) testing, and molecular diagnostics are also of significant interest, expected to play a crucial role in the future of IVD. The IVD market remains dynamic, characterized by constant innovations.

"In Vitro Diagnostic (IVD) Trends and Market Update: March 2024" by Kalorama Information provides the most current insights into these trends and others shaping the market. This report reflects the latest information available.

In "In Vitro Diagnostic (IVD) Trends and Market Update: March 2024", you'll discover:

  • What's Driving Growth in the IVD Market in 2024
  • What Major Trends are Affecting the Market in 2024
  • What Product Trends and New Developments Will Shape the IVD Market in 2024

Trends highlighted throughout 2023 and into 2024 include:

  • Growing interest in multiplex disease testing
  • Increasing interest in digital diagnostics, combining data and analytics with traditional IVD
  • Continued advancement of AI technologies
  • Growth in rapid and POC testing
  • And much more!

Kalorama Information remains dedicated to examining the IVD market and its evolving landscape, providing precise and up-to-date data through the expertise of its authors and its commitment to excellence in market analysis.

Table of Contents

Chapter 1: Worldwide IVD Market - March 2024 Update

  • IVD Market Demand and Growth
    • Figure 1-1: Quarter-by-Quarter Segment Performance Commentary, 2023
    • Table 1-1: Global In Vitro Diagnostic Sales by Product Market (Clinical Chemistry; Immunoassays: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab; Hematology - Core Lab; Microbiology (ID/AST); Microbiology (molecular); Microbiology - Mass Spectrometry; Coagulation (PT/INR); Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD), 2023 ($M)
    • Figure 1-2: IVD Quarterly Segment Performance, by Segment (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other), Q1 2022-Q4 2023 ($M)
    • Figure 1-3: IVD Segment Performance, by Segment (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other), Total Market Value, 2023 ($M)
  • COVID-19 Diagnostic Markets
    • Table 1-2: COVID-19 Product Sales, by Segment (Immunoassay [Antigen, Serology]; Molecular; Rapid), 2023 ($M)
  • Effect of COVID-19 on Market Segments
    • Table 1-3: IVD Market excluding and with COVID-19, 2023 ($M)
    • Figure 1-4: IVD Market Distribution, by Segment (COVID-19 Assays and Instruments; Excluding COVID-19 Assays and Instruments), 2023 (%)
    • Figure 1-5: IVD Market by COVID-19 and non-COVID markets, Quarterly Performance, 2024 ($M)
    • Table 1-4: Global In Vitro Diagnostic Market, by Segment (Clinical Chemistry; Immunoassays - non isotopic [Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab, Hematology - Core Lab]; Microbiology (ID/AST); Microbiology (molecular); Coagulation (PT/INR); Histology/cytology, d-dimer; Nucleic acid assays/genetic tests; Blood grouping/typing; Blood bank molecular - NAT Screens; POC, OTC diabetes; POC, OTC other; POC, professional/hospital), YoY Growth, 2022-2023 (%)
    • Figure 1-6: Global In Vitro Diagnostic Market, by Segment (Clinical Chemistry; Immunoassays - non isotopic [Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab, Hematology - Core Lab]; Microbiology (ID/AST); Microbiology (molecular); Coagulation (PT/INR); Histology/cytology, d-dimer; Nucleic acid assays/genetic tests; Blood grouping/typing; Blood bank molecular - NAT Screens; POC, OTC diabetes; POC, OTC other; POC, professional/hospital), YoY Growth, 2022-2023

Chapter 2: Product Trends and New Developments

  • Selected New - Q4 2023 and Q1 2024 - Core IVD Product Launches, Developments and Trends
  • Immunoassay
  • Molecular
  • Personalized Medicine and Genetic Testing
  • POC
  • Sequencing
  • Microbiology
  • Selected COVID-19 Developments - Q4 2023 - Q1 2024
    • Figure 2-1: COVID-19 Test Market, by Type (Antigen, Molecular, Rapid, Serology), Q1 2023-Q4 2023 - COVID-19 Testing Wanes ($M)

Chapter 3: Top IVD Market Participant Results

  • Selected Competitive Leader Updates
    • Figure 3-1: IVD Segment Growth, by Leading Competitors (Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Exact Sciences, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific), Change in Sales, 2022-2023 (%)
    • Figure 3-2: Changes in Market Distribution for IVD Sales, Top 10 Companies (Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Exact Sciences, Hologic, QuidelOrtho, Revvity, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Werlen, Others), 2020-2023 [Roche and Abbott Battle for #1 Spot]
    • Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche, 2021-2023 ($M)
  • Q4 2023, Q1 2024 M&A Activity
    • Table 3-1: Selected Diagnostic Market Mergers and Acquisitions Deals, Q4 2023-Q1 2024 ($M)
    • Figure 3-4: Count of IVD Industry M&A Deals, by Month, Full Year 2023 and Jan-Feb 2024
  • Abbott Laboratories
    • Table 3-2: Abbott Corporate Summary
    • Figure 3-5: Abbott Diagnostics Revenue, by Segment (Core Laboratory, Molecular, Point-of-Care, Rapid Diagnostics, COVID-19), Full Year 2022 and 2023 ($M)
  • Becton Dickinson and Co
    • Table 3-3: Becton Dickinson Corporate Summary
    • Figure 3-6: BD Life Sciences, Revenues by Business, FY End September 30, 2022, and 2023 ($M)
  • bioMerieux SA
    • Table 3-4: bioMerieux Corporate Summary
    • Figure 3-7: bioMerieux Clinical Applications, by Segment (Immunoassays, Microbiology, Molecular Biology, Other Lines), Full Year Results, 2022-2023 (Euro-M)
  • Danaher Corporation
    • Table 3-5: Danaher Corporation Summary
    • Figure 3-8: Danaher Diagnostic Segment Performance, Full Year Results, 2022-2023 ($M)
  • Exact Sciences, Inc.
    • Table 3-6: Exact Sciences Corporate Summary
    • Figure 3-9: Exact Sciences Segment Performance, by Segment Revenue (COVID-19 Testing, Precision Oncology, Screening), Full Year Results, FY 2022-FY 2023 ($M)
  • Hologic, Inc.
    • Table 3-7: Hologic Corporate Summary
    • Figure 3-10: Hologic Diagnostic Segment Performance, by Segments (Blood Screening, Cytology & Perinatal, Molecular Diagnostics), Full Year Results, FY 2022-FY 2023 ($M)
  • QuidelOrtho Corporation
    • Table 3-8: QuidelOrtho Corporate Summary
    • Figure 3-11: QuidelOrtho Financial Results, by Segment (Immunoassays, Molecular Diagnostics, Point-of-Care, Transfusion Medicine), 2022-2023 ($M)
  • Roche Diagnostic
    • Table 3-9: Roche Diagnostic Corporate Summary
    • Figure 3-12: Roche Diagnostics Revenue, by Product Group (Core Lab, Diabetes Care, Molecular, Pathology Lab, Point-of-Care), Full Year Results, 2022-2023 (CHF MN)
  • Siemens Healthineers
    • Table 3-10: Siemens Healthineers Corporate Summary
    • Figure 3-13: Siemens Diagnostics Revenue, FY 2022 and FY 2023 (Euro-M)
  • Sysmex Corporation
    • Table 3-11: Sysmex Corporate Summary
    • Figure 3-14: Sysmex Revenue, by Product Segment (Clinical Chemistry, FCM, Hematology, Hemostasis, Immunochemistry, Urinalysis, Others), FY 2022, 2023 and 2024 (JPY MN)
  • Thermo Fisher Scientific
    • Table 3-12: Thermo Fisher Scientific Corporate Summary
    • Figure 3-15: Thermo Fisher Scientific Business Segment Performance, by Segment (Analytical Instruments, Eliminations, Laboratory Products and Services, Life Sciences Solutions, Specialty Diagnostics), 2022-2023 ($M)

Chapter 4: New Opportunities

  • Artificial Intelligence Future Trends
  • At-Home Testing
  • Multiplex Testing
  • Telehealth